Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) generates frequent news related to its development of immuno-pharma therapeutics, particularly its flagship product candidate Ampligen (rintatolimod). Company announcements emphasize research and development in cancers, viral diseases, immune-deficiency disorders, and cancers with unmet medical needs, as well as updates on its intellectual property portfolio and corporate actions.
News coverage for AIM ImmunoTech often focuses on clinical and scientific milestones. Recent communications describe progress in the DURIPANC clinical program, where Ampligen is evaluated in combination with AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer, and presentations of data from a completed Phase 2 study in advanced recurrent ovarian cancer combining Ampligen with cisplatin and Merck’s Keytruda (pembrolizumab). The company also highlights publications in peer-reviewed journals and abstracts accepted at major scientific meetings such as the Society for Immunotherapy of Cancer (SITC).
Another recurring theme in AIM’s news is the expansion of its intellectual property. The company has announced a European patent covering compositions of its proprietary dsRNAs, including Ampligen, for treating Long COVID, and a patent in Japan for using Ampligen with checkpoint inhibitors for cancer treatment. These updates are presented as part of AIM’s strategy to strengthen protection around Ampligen in oncology and post‑COVID indications.
Investors following AIM ImmunoTech’s news will also see items on financial and corporate developments, including stock dividends, participation in investor conferences, public offerings of common stock and warrants, and financing agreements such as a promissory note with an institutional investor. Regular news releases on quarterly financial results, capital-raising transactions, and shareholder meetings provide additional context on the company’s operations and governance.
This news page aggregates such announcements so readers can review AIM ImmunoTech’s clinical updates, patent developments, financing activities, and corporate communications in one place.
AIM ImmunoTech (NYSE American: AIM) reported a significant increase in cash, reaching $40.3 million as of June 30, 2020, compared to $8.8 million at year-end 2019. The company's R&D expenses rose to $1.46 million from $1.10 million year-over-year. AIM is progressing with a Phase 1/2a trial of Ampligen combined with interferon alfa-2b for cancer patients with COVID-19, supported by agreements with key institutions. The company also aims to address post-COVID-19 chronic fatigue-like illnesses. AIM is pursuing approvals and launches for Ampligen in multiple markets.
AIM ImmunoTech (NYSE American:AIM) announced significant updates in its second-quarter 2020 report. The company's cash reserves increased to $40.3 million from $8.8 million at the end of 2019. Research and development expenses rose to $1.46 million, while general and administrative costs decreased to $1.72 million. AIM is engaged in various clinical trials, including a Phase 1/2a trial of Ampligen for cancer patients with COVID-19, and is collaborating with multiple institutions for further research into Ampligen's potential as a treatment and vaccine adjuvant.